The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | Phase I trial of BI 764532, a T-cell engager for DLL3-positive NEC and SCLC
Martin Wermke, MD, University Hospital Carl Gustav Carus, Dresden, Germany, presents findings from a Phase I trial (NCT04429087) of BI 764532, a DLL3/CD3 IgG-like T-cell engager, in patients with DLL3-positive small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC). Encouraging efficacy signals were reported, and duration of response (DOR) has not yet been reached. The T-cell engager additionally has an acceptable safety profile, where the adverse events reported did not hinder dose escalation efforts. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
